Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Predictive biomarkers are becoming increasingly important tools in drug development and
clinical research. The importance of using both guidelines for specimen acquisition and …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …

Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …

Results The overall median survival of the 168 patients was 13 months. The 1-year survival
was 54.3% and the 2-year survival was 12.9%. Univariate regression analysis indicated that …

Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …